

# A clinical trial investigating novel treatments for COVID-19 in the community

<b>Submission date</b> 28/10/2021	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 03/11/2021	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 22/08/2024	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data

## Plain English Summary

### Background and study aims

Despite a high uptake of COVID-19 vaccines, the disease remains prevalent around the world, with many patients experiencing considerable morbidity and requiring hospital admission. The COVID-19 pandemic is having a devastating effect on people's health and society. The risk of complications from COVID-19 is increased in people with underlying health conditions, unvaccinated people, and those in whom the vaccine is less effective, which can lead to significant medical problems, hospitalisation, and death. There is therefore an urgent need to identify treatments for COVID-19 for use in the community early on in the illness that speeds recovery and prevents the need for hospital admission.

Setting up a new clinical trial for each new treatment can be time-consuming and costly. This study is a platform, randomised controlled trial in the community that can test novel agents for treatment of COVID-19 for people at higher risk of complications. Using an efficient, open (no placebo) clinical trial design, we aim to get rapid answers in a flexible and cost-effective manner. The trial will allow further treatments of novel agents, should they become available, whilst the trial is already in progress. We aim to find suitable treatments for widespread use in the community to help those suffering from COVID-19 quicker and prevent Covid-related hospital admissions and death.

### Who can participate?

Patients through the UK who have a positive PCR or lateral flow test for COVID-19 which was taken in the last 7 days and are unwell with symptoms of COVID-19 that started in the last 5 days. These symptoms may include, but are not limited to, a high temperature; a new, continuous cough; loss or change to your sense of smell or taste; sore throat; shortness of breath; general feeling of being unwell; muscle pain; diarrhoea; vomiting; fever and cough.

The study website provides more information on how to take part: <https://www.panoramictrial.org/>

### What does the study involve?

Participants will be randomly allocated to receive usual treatment for COVID-19 or usual treatment plus the study treatment. In this study, the study treatment can be changed. Please see the trial website for details of the current study treatment.

### What are the possible benefits and risks of participating?

By taking part in this study, participants will be contributing towards the understanding of how doctors can treat COVID-19 and how the symptoms progress. This may help to reduce the duration and severity of symptoms when people fall ill and reduce the burden on the NHS during this crisis. Some participants may be asked to take part in sub-studies which involve providing blood samples and taking swabs. With any medicine, including ones that are already used within the NHS, there is a risk of side effects. Participants will be able to report whether they are experiencing any of these symptoms in the daily diary.

### Where is the study run from?

There will be PANORAMIC Hubs across the UK, managed by University of Oxford Primary Care and Vaccines Clinical Trials Unit co-operative (UK). However, all potential participants in the UK can enrol through the trial website.

### When is the study starting and how long is it expected to run for?

September 2021 to March 2025

### Who is funding the study?

1. Department of Health and Social Care
2. National Institute for Health Research (NIHR) (UK)

### Who is the main contact?

Prof. Christopher Butler  
panoramic@phc.ox.ac.uk

### Study website

<https://www.panoramictrial.org/>

## Contact information

### Type(s)

Scientific

### Contact name

Prof Christopher Butler

### ORCID ID

<http://orcid.org/0000-0002-0102-3453>

### Contact details

Nuffield Department of Primary Care Health Sciences  
University of Oxford  
Radcliffe Observatory Quarter  
Woodstock Road  
Oxford  
United Kingdom

OX2 6GG  
+44 (0)1865 289670  
panoramic@phc.ox.ac.uk

## Additional identifiers

**EudraCT/CTIS number**  
2021-005748-31

**IRAS number**  
1004274

**ClinicalTrials.gov number**  
Nil known

**Secondary identifying numbers**  
IRAS 1004274, NIHR135366, CPMS 51313

## Study information

**Scientific Title**  
Platform Adaptive trial of Novel antivirals for early treatment of COVID-19 in the community

**Acronym**  
PANORAMIC

**Study hypothesis**  
The main objective of the trial is to determine the effectiveness of selected antiviral agents in preventing hospitalisation and/ or death in higher-risk patients who are COVID-19 positive.

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**  
Approved 19/11/2021, South Central - Berkshire Research Ethics Committee (Bristol REC Centre, Temple Quay House, 2 The Square, Temple Quay, Bristol BS1 6PN, UK; no telephone number provided; berkshire.rec@hra.nhs.uk), ref: 21/SC/0393

**Study design**  
Platform randomized controlled trial

**Primary study design**  
Interventional

**Secondary study design**  
Randomised controlled trial

**Study setting(s)**  
Community, GP practice

## Study type(s)

Treatment

## Participant information sheet

<https://www.panoramictrial.org/participant-information>

## Condition

COVID-19 (SARS-Cov-2-infection)

## Interventions

A platform trial, in contrast to say a traditional two-arm design, allows multiple arms to be considered simultaneously, and interventions can be dropped and replaced as evidence emerges for effectiveness or lack of it. The intent is to establish an ongoing trial infrastructure within a master protocol that uses all the data already accumulated for the assessment of current and subsequently introduced interventions. New interventions will only be added after submission to the appropriate approval bodies.

The trial will initially be two arms comparing usual care to usual care + Antiviral agent (name hidden for blinding) treatment. four 200mg tablets (800mg) will be taken by participants every 12 hours (twice a day) for five days. This product is licensed for emergency use in the UK (i.e. under trial circumstances).

## Randomisation:

Participants will be randomised using a secure, fully validated and compliant web-based randomisation system. Once deemed eligible, the medically qualified clinician or research nurse from the central clinical team or Hub (as documented on the delegation log) will randomise the participant. Participants will be randomised to one study arm using equal allocation ratios corresponding to the number of eligible arms in the trial. For instance, if there are two active interventions (A & B), the allocation ratio will be 1:1:1 for Usual Care, active A, and active B (respectively), such that 33% of participants are randomised to Usual Care. If there are 3 active interventions, the allocation ratio will be 1:1:1:1, such that 25% of participants are randomised to Usual Care. Patients must be eligible for at least two arms (Usual Care and at least one novel antiviral intervention). Stratification will be by age and vaccination status.

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Antiviral agent (name hidden for blinding)

## Primary outcome measure

Non-elective hospitalisations/deaths in higher risk, symptomatic patients with confirmed COVID-19 within 28 days of randomisation measured using patient records.

## Secondary outcome measures

1. Time to recovery (defined as the first instance that a participant report feeling recovered from the illness) measured using daily online symptom scores. Telephone call or text on days 7, 14 and 28 if data is not obtained through the online diary. Also, at 3 and 6 months.

2. Participant reported illness severity, reported by daily rating of how well participant feels, enabling identification of sustained recovery.
3. Duration of severe symptoms and symptom recurrence measured using GP notes review if available through Oxford RCGP RSC network; otherwise, other sources of routinely collected data after 28 days. Medical notes review for up to 10 years.
4. Contacts with the health services reported by patients and/or captured by reports of patients' medical records up to 12 months
5. New infections in household measured using daily diary for 28 days
6. To investigate the safety of antiviral agents measured by the monitoring of adverse events (AEs as defined in the ISAs) up to 6 months
7. Longer term effects measured using patient contact at three and six months, electronic medical record search for up to one year
8. Cost effectiveness measured using resource use and cost data and EQ-5D-5L at baseline and day 28

**Overall study start date**

01/09/2021

**Overall study end date**

31/03/2025

## **Eligibility**

**Participant inclusion criteria**

Current participant inclusion criteria as of 02/11/2022:

1. Participant is able and willing to provide informed consent, or their legal representative is willing to provide informed consent
2. Symptoms attributable to COVID-19 started within the past 5 days and ongoing
3. A positive PCR or lateral flow SARS-CoV-2 test\*
4. Aged  $\geq 50$  years OR aged 18-49 years with one of the following known underlying chronic health conditions considered to make them clinically vulnerable:
  - 4.1. Chronic respiratory disease (including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication)
  - 4.2. Chronic heart or vascular disease
  - 4.3. Chronic kidney disease
  - 4.4. Chronic liver disease
  - 4.5. Chronic neurological disease (including dementia, stroke, epilepsy)
  - 4.6. Severe and profound learning disability
  - 4.7. Down's syndrome
  - 4.8. Diabetes mellitus (Type I or Type II)
  - 4.9. Immunosuppression: primary (e.g., inherited immune disorders resulting from genetic mutations, usually present at birth and diagnosed in childhood) or secondary due to disease or treatment (e.g., sickle cell, HIV, cancer, chemotherapy)
  - 4.10. Solid organ, bone marrow and stem cell transplant recipients
  - 4.11. Morbid obesity (BMI  $>35$ )
  - 4.12. Severe mental illness
  - 4.13. Care home resident
  - 4.14. Judged by recruiting medically qualified professional, research nurse, nurse prescriber, prescribing pharmacist, dependent on the ISA for the specific IMP involved, to be clinically

vulnerable

\*Any positive PCR or lateral flow test taken up to two days before symptom onset and randomisation qualifies.

Previous participant inclusion criteria:

1. Participant or their legal representative is able and willing to provide informed consent
2. Symptoms attributable to COVID-19 started within the past 5 days and ongoing
3. A positive PCR or lateral flow SARS-CoV-2 test within the past 7 days
4. Aged  $\geq 50$  years OR aged 18-49 years with any known underlying chronic health condition considered to make them clinically vulnerable:
  - 4.1. chronic respiratory disease (including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication)
  - 4.2. chronic heart or vascular disease
  - 4.3. chronic kidney disease
  - 4.4. chronic liver disease
  - 4.5. chronic neurological disease (including dementia, stroke, epilepsy)
  - 4.6. severe and profound learning disability
  - 4.7. Down's syndrome
  - 4.8. diabetes mellitus (Type or Type II)
  - 4.9. immunosuppression due to disease or treatment (e.g., sickle cell, HIV, cancer, chemotherapy)
  - 4.10. solid organ, bone marrow and stem cell transplant recipients
  - 4.11. morbid obesity (BMI  $>35$ )
  - 4.12. severe mental illness
  - 4.13. care home resident
  - 4.14. judged by recruiting clinician or research nurse (registered medical practitioner or trained study nurse) to be clinically vulnerable

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

30,000

**Total final enrolment**

29295

**Participant exclusion criteria**

Current participant exclusion criteria as of 02/11/2022:

1. Patient currently admitted to hospital (inpatient)
2. Previous randomisation in the PANORAMIC trial

3. Currently participating in a clinical trial of a therapeutic agent for acute COVID-19
4. Additional exclusions specific to each intervention arm, if any, as listed in the Intervention Specific Appendices (ISA's) of currently open trial arms

Previous participant exclusion criteria:

1. Patient currently admitted to hospital
2. Previous randomisation in the PANORAMIC trial
3. Currently participating in a clinical trial of a therapeutic agent for acute COVID-19
4. Participation in an investigational COVID-19 vaccine trial within previous 28 days
5. Additional exclusions specific to each intervention arm, if any, as listed in the Intervention Specific Appendices (ISA's) of currently open trial arms

**Recruitment start date**

08/12/2021

**Recruitment end date**

28/03/2024

## Locations

**Countries of recruitment**

England

Northern Ireland

Scotland

United Kingdom

Wales

**Study participating centre**

**Open to all eligible participants throughout the UK**

PC-CTU, Dept of Primary Health Care Sciences

University of Oxford

Gibson Building

Radcliffe Observatory Quarter

Woodstock Road

Oxford

United Kingdom

OX2 6GG

## Sponsor information

**Organisation**

University of Oxford

**Sponsor details**

Research Governance, Ethics and Assurance (RGEA)  
Joint Research Office  
1st Floor  
Boundary Brook House  
Churchill Drive  
Headington  
Oxford  
England  
United Kingdom  
OX3 7GB  
+44 (0)1865 616480  
rgea.sponsor@admin.ox.ac.uk

**Sponsor type**

University/education

**Website**

<http://www.ox.ac.uk/>

**ROR**

<https://ror.org/052gg0110>

**Funder(s)****Funder type**

Government

**Funder Name**

Department of Health and Social Care

**Alternative Name(s)**

Department of Health & Social Care, DH

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

**Funder Name**



National Institute for Health Research

### Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

### Intention to publish date

31/03/2025

### Individual participant data (IPD) sharing plan

Selected, de-identified individual participant data for outcome measures will be available on request, accompanied by a protocol outlining hypotheses and proposed analytic methods, by contacting the corresponding author (panoramic@phc.ox.ac.uk): requests will be considered by a Departmental Committee. A contract should be signed.

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Molnupiravir results	22/12/2022	28/12/2022	Yes	No
<a href="#">Participant information sheet</a>			17/02/2023	No	Yes
<a href="#">Protocol file</a>	version 6.0	15/11/2022	22/02/2023	No	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Protocol article</a>		07/08/2023	09/08/2023	Yes	No
<a href="#">Results article</a>	molnupiravir SARS-CoV-2 viral and antibody response	23/02/2024	26/02/2024	Yes	No